WACKER completed the acquisition of ADL BioPharma from Kartesia for €100m.

WACKER, a German multinational chemical company, completed the acquisition of ADL BioPharma, a pharmaceutical company, from Kartesia, a private equity firm, for €100m. “Acquiring ADL BioPharma is an important step in the continued growth of our biotechnology business, with which we expect to generate one billion euros in sales in 2030. Development at ADL BioPharma has been very good in recent years, and their sales have grown considerably. The additional fermentation capacities will provide a foundation for growth in the field of sustainably produced dietary ingredients. WACKER’s technological expertise combined with the capacities of ADL BioPharma will make us a much stronger player on this growth market,” Christian Hartel, WACKER CEO.